Display options
Cite
Kadowaki T, Tajima N, Odawara M, et al. Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks. J Diabetes Investig. 2012;4(2):174-81doi: 10.1111/jdi.12001.
Kadowaki, T., Tajima, N., Odawara, M., Nishii, M., Taniguchi, T., & Ferreira, J. C. (2013). Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks. Journal of diabetes investigation, 4(2), 174-81. https://doi.org/10.1111/jdi.12001
Kadowaki, Takashi, et al. "Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks." Journal of diabetes investigation vol. 4,2 (2013): 174-81. doi: https://doi.org/10.1111/jdi.12001
Kadowaki T, Tajima N, Odawara M, Nishii M, Taniguchi T, Ferreira JC. Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks. J Diabetes Investig. 2013 Mar 18;4(2):174-81. doi: 10.1111/jdi.12001. Epub 2012 Oct 22. PMID: 24843649; PMCID: PMC4019272.
Copy Download .nbib Format: NLM
Share it on

J Diabetes Investig. 2013 Mar 18;4(2):174-81. doi: 10.1111/jdi.12001. Epub 2012 Oct 22.

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks.

Journal of diabetes investigation

Takashi Kadowaki, Naoko Tajima, Masato Odawara, Mikio Nishii, Tadaaki Taniguchi, Juan Camilo Arjona Ferreira

Affiliations

  1. Graduate School of Medicine The University of Tokyo Tokyo Japan.
  2. Jikei University School of Medicine Tokyo Japan.
  3. The Third Department of Internal Medicine Tokyo Medical University Tokyo Japan.
  4. Development Planning Ono Pharmaceutical Co., Ltd Osaka Tokyo Japan.
  5. MSD K. K Tokyo Japan.
  6. Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc Whitehouse Station NJ USA.

PMID: 24843649 PMCID: PMC4019272 DOI: 10.1111/jdi.12001

Abstract

AIMS/INTRODUCTION: The efficacy and safety of sitagliptin, a highly selective dipeptidyl peptidase-4 inhibitor, when added to metformin monotherapy was examined in Japanese patients with type 2 diabetes.

MATERIALS AND METHODS: In this 52-week, add-on to metformin study, 149 patients were randomly assigned to receive sitagliptin 50 mg or placebo once daily in a double-blind fashion for 12 weeks. Thereafter, all patients who completed the double-blind period of the study received open-label sitagliptin 50 mg once daily for 40 weeks, with the investigator option of increasing sitagliptin to 100 mg once daily for patients who met predefined glycemic thresholds.

RESULTS: After 12 weeks of treatment, the mean change from baseline in glycated hemoglobin (HbA1c) significantly decreased with sitagliptin relative to placebo (between-group difference [95% confidence interval] = -0.7% [-0.9 to -0.5] P < 0.001). At week 12, the mean changes in 2-h post-meal glucose (-2.6 mmol/L [-3.5 to -1.7]) and fasting plasma glucose (-1.0 mmol/L [-1.3 to -0.6]) also decreased significantly with sitagliptin relative to placebo (P < 0.001 for both). Significant improvements from baseline in glycemic control were also observed in the open-label period through to week 52. There were no differences between treatment groups in the incidence of adverse events (AEs), including hypoglycemia and predefined gastrointestinal AEs (nausea, vomiting and diarrhea) during the double-blind period, with similar findings in the open-label period.

CONCLUSIONS: Over a period of 52 weeks, the addition of sitagliptin once-daily to ongoing metformin therapy was efficacious and generally well tolerated in Japanese patients with type 2 diabetes. This trial was registered with ClinicalTrials.gov (no. NCT00363948).

Keywords: Metformin; Sitagliptin; Type 2 diabetes

References

  1. Diabetes Res Clin Pract. 2004 Dec;66 Suppl 1:S37-43 - PubMed
  2. Curr Med Res Opin. 2007 Jul;23(7):1493-507 - PubMed
  3. Clin Ther. 2006 Oct;28(10):1556-68 - PubMed
  4. Curr Med Res Opin. 2008 Feb;24(2):537-50 - PubMed
  5. Diabetes Obes Metab. 2007 Sep;9(5):733-45 - PubMed
  6. Diabetes Obes Metab. 2010 Jul;12(7):613-22 - PubMed
  7. Diabetes Care. 2012 Jun;35(6):1364-79 - PubMed
  8. Diabetes. 1988 Jun;37(6):667-87 - PubMed
  9. JAMA. 2002 Jan 16;287(3):360-72 - PubMed
  10. Diabet Med. 2007 Apr;24(4):350-8 - PubMed
  11. Diabetes Care. 2006 Dec;29(12):2638-43 - PubMed
  12. J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9 - PubMed
  13. J Diabetes Investig. 2012 Feb 20;3(1):39-40 - PubMed
  14. Diabetes Res Clin Pract. 2003 Jan;59(1):71-7 - PubMed
  15. Diabetes Res Clin Pract. 2009 Jan;83(1):106-16 - PubMed
  16. Diabet Med. 2006 Jun;23(6):579-93 - PubMed
  17. Diabetes Care. 2006 Dec;29(12):2632-7 - PubMed
  18. Clin Pharmacol Ther. 2010 Dec;88(6):801-8 - PubMed
  19. Diabetes. 2000 Dec;49(12):2063-9 - PubMed
  20. Diabetes Obes Metab. 2010 Feb;12(2):167-77 - PubMed
  21. Diabetes Care. 2007 Aug;30(8):1979-87 - PubMed

Publication Types